Medivir AB (Medivir AB) Price-to-Tangible-Book : 3.85 (As of May. 01, 2024)

View and export this data going back to . Start your Free Trial

What is Medivir AB Price-to-Tangible-Book?

As of today (2024-05-01), Medivir AB's share price is $0.82. Medivir AB's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.21. Hence, Medivir AB's Price to Tangible Book Ratio of today is 3.85.

The historical rank and industry rank for Medivir AB's Price-to-Tangible-Book or its related term are showing as below:

MVRBF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.62 Med: 2.61 Max: 5.72
Current: 2.83

During the past 13 years, Medivir AB's highest Price to Tangible Book Ratio was 5.72. The lowest was 1.62. And the median was 2.61.

MVRBF's Price-to-Tangible-Book is ranked worse than
50.61% of 1221 companies
in the Biotechnology industry
Industry Median: 2.69 vs MVRBF: 2.83

A closely related ratio is called PB Ratio. As of today, Medivir AB's share price is $0.82. Medivir AB's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.38. Hence, Medivir AB's P/B Ratio of today is 2.15.

Medivir AB Price-to-Tangible-Book Historical Data

The historical data trend for Medivir AB's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Price-to-Tangible-Book Chart

Medivir AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

6.96

6.79

3.40

4.43

Medivir AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															4.43	6.17	-	-	-

Competitive Comparison of Medivir AB's Price-to-Tangible-Book

For the Biotechnology subindustry, Medivir AB's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medivir AB's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Medivir AB's Price-to-Tangible-Book falls into.

Medivir AB Price-to-Tangible-Book Calculation

Medivir AB's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	0.82	/	0.213
	=	3.85

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Medivir AB Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Medivir AB's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Medivir AB (Medivir AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

MVIR:Sweden MVR0:Germany

Address

Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22

Website

https://www.medivir.com

Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.